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1674Increased Cardiometabolic Traits in Pediatric
Survivors of Acute Lymphoblastic Leukemia Treated
with Total Body Irradiation
Eric J. Chow,1,2 Jill H. Simmons,3 Christian L. Roth,2
K. Scott Baker,1,2 Paul A. Hoffmeister,1 Jean E. Sanders,1,2 Debra L. Friedman3Survivors of childhood acute lymphoblastic leukemia (ALL) may face an increased risk of metabolic and car-
diovascular late effects. To determine the prevalence of and risk factors for adverse cardiometabolic traits in
a contemporary cohort of pediatric ALL survivors, we recruited 48 off-therapy patients in remission treated
with conventional chemotherapy and 26 treated with total body irradiation (TBI)-based hematopoietic cell
transplantation (HCT) in this cross-sectional pilot study. At a median age of 15 years (range, 8-21 years),
HCT survivors were significantly more likely than non-HCT survivors to manifest multiple cardiometabolic
traits, including central adiposity, hypertension, insulin resistance, and dyslipidemia. Overall, 23.1% of HCT
survivors met the criteria for metabolic syndrome ($3 traits), compared with 4.2% of non-HCT survivors
(P5 .02). HCT survivors also had increased C-reactive protein and leptin levels and decreased adiponectin,
suggestive of underlying inflammation and increased visceral fat. In multivariate analyses, history of HCT
remained associated with $2 traits (odds ratio [OR]. 5.13; 95% confidence interval [CI], 1.54-17.15) as
well as with $3 traits (OR, 16.72; 95% CI, 1.66-168.80). Other risk factors included any cranial radiation
exposure and family history of cardiometabolic disease. In summary, pediatric ALL survivors exposed to
TBI-based HCT as well as to any cranial radiation may manifest cardiometabolic traits at an early age and
should be screened accordingly.
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The cure rate of childhood acute lymphoblastic leu-
kemia (ALL) now exceeds 85%, resulting in a growing
cohort of long-term survivors who potentially face
adverse long-term health sequelae as a result of their
cancer therapy [1]. There is evidence that ALL survivors
treated with conventional therapy alone or with hema-
topoietic cell transplantation (HCT) are at increased1Clinical Research Division, Fred Hutchinson Cancer
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6/j.bbmt.2010.05.016risk of developing multiple related cardiovascular/
metabolic risk factors, inluding obesity, hypertension,
dyslipidemia, and insulin resistance [2-6]. Together,
these components make up the metabolic syndrome,
which is associated with a significantly increased
risk of both atherosclerotic cardiovascular disease and
diabetes mellitus [7-9]. Among ALL survivors, risk
may be increased secondary to growth hormone
deficiency occurring after cranial radiotherapy and
total body irradiation (TBI), which has been
associated with obesity and dyslipidemia [3,10].
Because chronic inflammation may have an important
role in mediating obesity, insulin resistance, and
related cardiovascular diseases [11], chronic graft-
versus-host disease (cGVHD) posttransplantation also
may increase the risk in affected survivors [12,13].
Other exposures, such as high-dose glucocorticoids (as
part of both primary leukemia treatment and GVHD
treatment) and more widespread use of immunosup-
pressive medications, such as calcineurin inhibitors
used to prevent or treat GVHD, also have been
associated with obesity, hypertension, and dyslipidemia
[14,15].
Biol Blood Marrow Transplant 16:1674-1681, 2010 1675Cardiometabolic Traits After Pediatric LeukemiaBecause current ALL therapy is characterized by
reduced use of cranial radiotherapy and increased use
of more-intensive chemotherapy, including more
potent glucocorticoids, we conducted this prospective
cross-sectional pilot study to determine the prevalence
of and risk factors for cardiometabolic traits in pediat-
ric ALL survivors treated since 1990 with conventional
chemotherapy and with HCT. We hypothesized that
childhood HCT survivors would be at increased risk
for these traits compared with ALL survivors treated
without HCT, and that this risk would be further
modified by a history of GVHD and cranial radiother-
apy exposure. In exploratory analysis, we also mea-
sured selected cytokines in an attempt to determine
whether levels of cytokines associated with inflamma-
tion, adiposity, and endothelial dysfunction would be
altered in survivors with multiple cardiometabolic
traits.SUBJECTS AND METHODS
Subjects
Eligible subjects for this prospective cross-
sectional study were diagnosed with ALL at age\22
years; treated at Seattle Children’s Hospital, Fred
Hutchinson Cancer Research Center, or Vanderbilt
Children’s Hospital between 1990 and 2008; and
currently aged 8-21 years. Two patient cohorts were
recruited, one consisting of individuals in first com-
plete remission after treatment with conventional che-
motherapy and the other consisting of individuals
treated with HCT, currently in remission, and off
any immunosuppressive therapy for GVHD. All sub-
jects had to be at least 1 year off therapy or out from
the date of HCT. Subjects were recruited in Seattle
between July 2007 and June 2009 and in Nashville be-
tween April and June 2009. Among the 41 HCT and
83 non-HCT patients approached for this study,
63.4% and 66.3%, respectively, were enrolled. Seven
enrolled non-HCT patients were subsequently ex-
cluded (because of Down syndrome in 3 and incom-
plete data in 4). Final data analysis included 26 HCT
and 48 non-HCT survivors. The Institutional Review
Boards at all participating centers approved the study
protocol, and all participants/guardians provided
written informed consent before participation.Exposure and Outcome Measurements
Medical records were abstracted for previous che-
motherapy and radiotherapy doses, including those as-
sociated with HCT, history of extensive or moderate/
severe cGVHD, and any clinician-reported growth hor-
mone deficiency.Medical historieswere updated for any
patient whowas not seenwithin the previous year at one
of the participating centers. Participants and theirparents also completed questionnaires on physical activ-
ity [16], diet/food frequencies [17], and family history of
cardiovascular disease (ie, coronary heart disease, stroke,
hypertension, dyslipidemia) and/or diabetes [18]. Posi-
tive family history was defined as having a first-degree
relative with the relevant disease.
Height, weight, and waist and hip circumferences
were measured, and body mass index (BMI) and
waist-to-hip ratio were calculated. Resting blood pres-
sure wasmeasured twice, with a thirdmeasurement ob-
tained if systolic or diastolic pressures were .10 mm
Hg apart; the most extreme measurement was
excluded. Pediatric normative data were used to deter-
mine BMI z score [19], waist circumference [20], and
blood pressure percentiles [21].
At the same research visit, when possible, following
an 8-hour overnight fast, blood samples were obtained
for a lipid profile (total cholesterol, high-density lipo-
protein [HDL], and triglycerides), glucose, insulin,
and selected cytokines (leptin, adiponectin, high sensi-
tivity C-reactive protein [CRP], interleukin [IL]-6,
tumor necrosis factor [TNF]-a, E-selectin, and soluble
intercellular and vascular cell adhesion molecules
[sICAM, sVCAM]). Lipid profiles were collected and
processed at the participating institutions’ hospital labo-
ratories. Glucose was measured using an automated
hexokinase method (Roche Diagnostics, Indianapolis,
IN), and insulin was measured using an automated
immunoenzymometeric assay (Tosoh Bioscience, San
Francisco, CA). Cytokines were collected and processed
under a standardized protocol [22] and then stored at
280C before being batch analyzed using a commer-
cially available fluorokine multianalyte profiling kit
(R&D Systems, Minneapolis, MN) on a Luminex 200
analyzer (Luminex, Austin, TX). As ameasure of insulin
resistance, the homeostasis model assessment (HOMA)
was calculated from fasting glucose and insulin values
[23], based on the following formula: glucose (mmol/
L) insulin (mU/L)/22.5.
Cardiometabolic traits were defined a priori via
current adult International Diabetes Foundation
Consensus criteria [9] for subjects aged $18 years
and pediatric-adapted values for those aged\18 years
(Table 1). Sensitivity analysis used criteria based on the
older but still widely used National Cholesterol Edu-
cation Program Adult Treatment Panel III (ATP III)
guidelines [7,8], with a fasting glucose level $100
mg/dL defined as abnormal. For this study, we
tabulated the number of abnormal components
present in each individual and categorized individuals
as having the metabolic syndrome if any 3 or more of
the 5 criteria were present.Statistical Analyses
Continuous parameters with skewed distributions
were transformed when possible. Differences in
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1676 Biol Blood Marrow Transplant 16:1674-1681, 2010E. J. Chow et al.continuous parameters were compared using the t test
(or Wilcoxon’s rank-sum test for nonnormal distribu-
tions), and differences in proportions were assessed by
Fisher’s exact test. All tests were 2-sided. Multivariate
linear regression models that included current age, sex,
and participating institution (Seattle vs Nashville) were
used to assess differences in physical activity and diet
(ie, calories, fat intake) between patient cohorts. Linear
regression models that also included BMI z scores and
the presence of multiple cardiometabolic traits ($2 vs
\2)were used to assess differences in cytokine levels be-
tween patient cohorts. Logistic regression models that
included the foregoing adjustment variables plus race/
ethnicity (white v. nonwhite) and family history of car-
diovascular disease/diabetes were also used to estimate
the odds ratios (OR) and 95% confidence intervals
(CI) of having $2 cardiometabolic traits associated
with potential risk factors of HCT status, cranial radio-
therapy, cGVHD, and growth hormone deficiency. All
analyses were performed using Stata version 10 (Stata-
Corp, College Station, TX).RESULTS
Demographic Data and Treatment
Characteristics
Basic demographic characteristics were similar for
the 2 survivor cohorts (Table 2). Compared with re-
sponders, nonresponders were slightly more likely to
be female (55.8%), but the 2 groups were of similar
current median age (16 years; range, 8-21 years) and
median years since ALL diagnosis (9 years; range,
3-19 years). The proportion of subjects with any family
history of cardiovascular disease and/or diabetes was
greater in the HCT survivors compared with the
non-HCT survivors (61.5% vs 37.5%; P 5 .06). Re-
flecting contemporary treatment, only 10.4% of the
non-HCT group received any cranial radiotherapy
(all 1800 cGy), in contrast to theHCT group, in which
38.5% received some form of cranial radiotherapy, ei-
ther as upfront therapy or as salvage therapy for recur-
rence (median, 1000 cGy; range, 600-2400 cGy). All
HCT patients were conditioned with myeloablative
doses of cyclophosphamide and TBI (median dose,
1320 cGy; range, 1200-1575 cGy). In the HCT recip-
ients, bone marrow was the predominant stem cell
source (n 5 19; 73.1%), followed by peripheral blood
(n 5 5) and cord blood products (n 5 2). Twenty-one
transplants (80.8%) were HLA-matched, 11 with
a matched unrelated donor. No patient underwent
more than one HCT procedure. Thirteen HCT survi-
vors and 1 non-HCT survivor subsequently developed
growth hormone deficiency. Nine subjects were
currently receiving growth hormone supplementation.
Table 2. Demographic and Treatment Characteristics of ALL Survivors Stratified by HCT Status
Characteristic Non-HCT (n 5 48) HCT (n 5 26) P Value
Site, n (%)
Seattle 30 (62.5) 21 (80.8) .12
Nashville 18 (37.5) 5 (19.2)
Female, n (%) 26 (54.2) 10 (38.5) .23
Nonwhite race/ethnicity, n (%) 10 (20.8) 8 (30.8) .40
Median current age, years (range) 14 (8-21) 15 (8-21) .36
Median years (range) since diagnosis 10 (3-18) 10.5 (1-15) .83
Median years (range) since HCT – 6 (1-13) –
History of relapse, n (%)* – 16 (61.5) –
Radiation exposure, n (%)
Cranial radiotherapy 5 (10.4) 10 (38.5) .007
TBI – 26 (100) –
History of chronic GVHD, n (%) – 16 (61.5) –
HCT indicates hematopoietic cell transplant; TBI, total body irradiation; GVHD, graft-versus-host disease.
*Eligibility for the non-HCT cohort was restricted to those in first complete remission. Ten HCT patients underwent transplantation while in first com-
plete remission because of very-high-risk disease in accordance with institutional practice.
Biol Blood Marrow Transplant 16:1674-1681, 2010 1677Cardiometabolic Traits After Pediatric LeukemiaAnthropometric and Standard Laboratory
Measurements
Although HCT survivors were significantly shorter
than non-HCT survivors, the distribution of BMI z
scores and the proportion of overweight or obese
individuals asdefinedbyBMIwere similar in the2groups
(42.3% vs 39.6%, respectively; Table 3). The propor-
tions defined as obese using BMI versus waist circumfer-
ence alsowere similar in the 2groups; however, theHCT
survivors had significantly greater waist-to-hip ratios,
even after adjustment for sex and current age (Table 3).
HCT survivors weremore likely to have blood pres-
sures$90th percentile for age, sex, and height (or abso-
lute values$120/80mmHg) comparedwith non-HCT
survivors (Table 3). However, the proportions with
blood pressures $95th percentile or $140/90 mm Hg
were similar (11.5 vs 8.3%; P 5 .69). Whereas median
glucose values were similar for the 2 survivor cohorts,
HCT survivors had significantly higher fasting insulin
levels and measures of insulin resistance as estimated
by HOMA (both P \ .01). HCT survivors also had
significantly more adverse lipid profiles with higher
triglyceride levels and lower HDL levels (both P\ .01).
When the number of survivorsmeeting cardiometa-
bolic trait criteria was tabulated, compared with non-
HCT survivors, significantly greater proportions of
HCT survivors met at least 1 criterion (84.6% vs
50.0%) andmet at least 3 criteria (23.1%vs 4.2%; global
P value\ .01) (Table 3).When criteria were reanalyzed
using the ATP III guidelines, the burden of traits
remained greater in theHCT survivors (P5 .04).How-
ever, obesity, as defined by BMI, was more common in
non-HCT survivors with $2 traits compared with
HCT survivors (9 [90%] vs 5 [35.7%]; P5 .01).
Cytokine Levels
Compared with non-HCT survivors, HCT survi-
vors had significantly lower adiponectin and higher
CRP levels, and borderline higher leptin levels
(Figure 1). Markers of endothelial dysfunction(sICAM, vCAM, and E-selectin) were similar in the
2 groups.Weobtained IL-6 andTNF-a levels in a sub-
set of subjects in each group (non-HCT, n 5 23;
HCT, n 5 14), and found no significant differences
between the groups. When HCT and non-HCT sur-
vivors were combined and stratified by the presence
of\2 versus $2 cardiometabolic traits, leptin, CRP,
and E-selectin levels were significantly higher and adi-
ponectin level was significantly lower in those with$2
traits. Among HCT recipients alone, history of HLA
disparity and chronic GVHD were not associated
with significant differences in cytokine levels.Multivariate Analyses
In adjusted analyses, a history of HCT remained
a significant risk factor for having $2 cardiometabolic
traits (OR, 5.13; 95% CI, 1.54-17.15), as well as for
meeting criteria for metabolic syndrome ($3 traits;
OR, 16.72; 95% CI, 1.66-168.80). Using ATP III cri-
teria instead, a history of HCT remained significant
($2 traits: OR, 4.16; 95% CI, 1.07-16.10; $3 traits:
OR, 22.99, 95% CI, 1.41-373.65). Compared with
those who had no radiotherapy exposure to the brain,
survivors treated with cranial radiotherapy/TBI alone
and cranial radiotherapy plus TBI had a similar risk
of manifesting $2 cardiometabolic traits (OR, 5-6).
Positive family history also was significantly associated
with $2 traits independent of HCT status (OR, 3.65;
95% CI, 1.15-11.57). However, diagnosis age, time
since diagnosis, sex, and history of cGVHD or growth
hormone deficiency (even if those currently receiving
supplementation were considered separately) were
not associated with having $2 traits.
Risk estimates were not associated with or modi-
fied by the addition of physical activity or caloric intake
levels, even though HCT survivors had lower activity
scores and borderline lower caloric intake compared
with non-HCT survivors (Table 4). However, the pro-
portion of calories from fats was similar in the 2 groups
(data not shown).
Figure 1. Distribution of selected biomarkers stratified by HCT status: adiponectin, leptin, CRP, sICAM, sVCAM, and E-selectin. Boxes show median
values and interquartile ranges, with whiskers denoting upper and lower adjacent values; outside values are denoted by closed circles. Differences
between HCT survivors and non-HCT survivors were significant for adiponectin and CRP (P\.001 and P5.02, respectively); the distributions of other
biomarkers were not significantly different in unadjusted analyses (leptin, P 5 .08; sICAM, P 5 .17; sVCAM, P 5 .96; E-selectin, P 5 .19).
1678 Biol Blood Marrow Transplant 16:1674-1681, 2010E. J. Chow et al.In linear regression models, HCT status was signif-
icantly associated with lower adiponectin levels and
higher leptin levels (Table 4); however, HCT status
was no longer associatedwith increasedCRP level inde-
pendent of the presence of $2 traits. History of HLA
disparity, cGVHD, growth hormone deficiency, and ra-
diation exposure to the brain were not associated with
differences in cytokine levels in our adjusted analyses.DISCUSSION
Various follow-up studies of adult survivors of pe-
diatric ALL have reported increased obesity, insulin
resistance, and dyslipidemia [3,5,6]. Among studiesthat have specifically examined transplant survivors,
both pediatric and adult HCT recipients appear to
be at increased risk of cardiometabolic traits,
particularly dyslipidemia [2,4,24-27]. HCT survivors
also have been reported to have an increased risk of
developing diabetes [25,28,29] and cardiovascular
disease [30-32]. However, few previous studies have
directly compared pediatric ALL HCT and non-
HCT survivors, particularly survivors treated in the
contemporary era when cranial radiotherapy is used
less commonly but chemotherapy is more intensive.
Our results suggest that young HCT survivors uni-
formly treated with TBI are at significantly greater
risk for developing cardiometabolic traits and the
Table 3. Metabolic Parameters of ALL Survivors, Stratified by HCT Status
Outcomes Non-HCT (n 5 48) HCT (n 5 26) P Value
Height z score, mean ± SD 0.30 ± 0.99 20.59 ± 1.19 <.01
BMI z score, mean ± SD 0.80 ± 0.92 0.54 ± 1.29 .31
BMI $25 or $85th percentile for age and sex, n (%) 19 (39.6) 11 (42.3) 1.00
BMI $30 or $95th percentile for age and sex, n (%) 13 (27.1) 6 (23.1) .79
Waist $90th percentile for age and sex, n (%)* 13 (27.1) 7 (26.9) 1.00
Waist-to-hip ratio, mean ± SD 0.83 ± 0.07 0.90 ± 0.068 <.01
Blood pressure $120/80 mm Hg or $90th percentile for age, sex, and height, n (%) 8 (16.7) 11 (42.3) .03
Glucose, mg/dL, median (range) 82 (43-96) 82 (63-110) .76
Insulin, mU/L, median (range) 6.5 (1.0-26.9) 11.7 (1.0-39.6) <.01
HOMA-IR, median (range) 1.32 (0.11-5.51) 2.64 (0.18-10.76) <.01
Triglycerides, median (range), mg/dL 63 (16-177) 127 (63-327) <.01
HDL, median (range), mg/dL 54 (33-108) 45 (32-63) <.01
Cardiometabolic traits, n (%)†
0 24 (50.0) 4 (15.4) Overall
<.011 14 (29.2) 8 (30.8)
2 8 (16.7) 8 (30.8)
$3 2 (4.2) 6 (23.1)
HCT indicates hematopoietic cell transplantation; HOMA, homeostasis model assessment.
*Or if waist circumference $80 cm in females and $94 cm in males.
†As defined by the consensus criteria (Table 1).
Biol Blood Marrow Transplant 16:1674-1681, 2010 1679Cardiometabolic Traits After Pediatric Leukemiametabolic syndrome compared with similar-aged non-
HCT survivors not exposed to cranial radiotherapy.
Although the power of the present study was limited,
additional cranial radiotherapy did not appear to
markedly increase the risk beyond that associated
with TBI. Although no standard pediatric definition
of metabolic syndrome exists, and prevalence estimates
can vary depending on the criteria used [33], our find-
ings were consistent across 2 classification schemes.
The finding that cardiometabolic changes may
occur soon after treatment in childhood is important,
given that data from the general population suggest
that cardiometabolic traits that develop in childhood
often persist into adulthood [34,35]. However, in
contrast to findings from the general population [8]
and in our non-HCT ALL survivors, HCT survivors
often manifest cardiometabolic traits, such as dyslipi-
demia and insulin resistance, without being ‘‘obese’’Table 4. Multivariate Regression Estimates (Coefficients
with 95% CIs) for Selected Parameters in ALL Survivors, Ad-
justed for Sex, Current Age, Race/Ethnicity, and Institution
Parameter Non-HCT HCT P Value
Physical activity* Ref -1.62 (-2.90 to -0.34) .01
Calories* Ref -0.21 (-0.42 to -0.002) .048
Biomarkers†
Adiponectin* Ref -0.32 (-0.52 to -0.13) .01
Leptin* Ref 1.01 (0.55 to 1.46) <.01
CRP* Ref 0.43 (-0.33 to 1.19) .26
sICAM* Ref 0.14 (-0.01 to 0.30) .07
sVCAM Ref 0.03 (-0.02 to 0.08) .24
E-selectin Ref 2.54 (-8.11 to 13.19) .64
Ref indicates referent group; ALL, acute lymphoblastic leukemia; HCT,
hematopoietic cell transplantation; CRP, C reactive protein; sICAM,
soluble intercellular cell adhesion molecules; sVCAM, soluble vascular
cell adhesion molecules.
*Logarithmically transformed to normalize data distribution.
†Also adjusted for BMI z score and the presence of $2 metabolic syn-
drome traits.as defined by BMI [24,27,29]. Instead, more direct
measures of central/abdominal adiposity, such as
waist-to-hip ratio, may be a more useful screening
tool in the HCT population. In the general popula-
tion, central adiposity is correlated with visceral fat
and has been shown to be an independent risk factor
for cardiovascular disease and diabetes, even after
adjusting for BMI [8,9,36].
Consistent with previous studies [3,4,6,25,37], we
found that both TBI and cranial radiotherapy were
strongly associated with subsequent metabolic
abnormalities. Both of these are known risk factors for
subsequent growth hormone deficiency. Although we
did not find a history of growth hormone deficiency
(regardless of supplementation) to be an independent
risk factor for increased cardiometabolic traits, our
patients were not prospectively tested for this study,
and it is possible that some patients might have
undiagnosed deficiency, particularly postpubertal
patients, for whom short stature is less of a concern.
Other studies that prospectively tested all participants
for growth hormone deficiency found that those with
growthhormonedeficiencywere at increased risk [3,38].
In addition to TBI, other factors associated with
allogeneic HCTmight be associated with an increased
risk for cardiometabolic complications. Large adult
series have found an increased risk of cardiovascular
complications in allogeneic HCT recipients compared
with autologous HCT recipients, even after adjusting
for TBI exposure [25,30]. Some evidence suggests
that GVHD following allogeneic HCT can result in
chronic low-level inflammation, endothelial dysfunc-
tion, and an atherosclerotic phenotype [12,13,39].
Although we did not find history of cGVHD to be
associated with differences in cytokine levels or to be
an independent risk factor for the development of
multiple cardiometabolic traits, this might be related
1680 Biol Blood Marrow Transplant 16:1674-1681, 2010E. J. Chow et al.to our limited sample size and our exclusion of patients
still being actively treated for GVHD. A larger study
with a more detailed analysis of GVHD (eg, duration
of treatment, severity/extent) might yet reveal more
subtle effects of GVHD, as well as other factors,
such as stem cell source and HLA disparity, that may
influence immune tolerance, inflammation, and the
development of cardiometabolic outcomes.
Chronic inflammation appears to be a central path-
ophysiological mechanism underlying the development
of diabetes and atherosclerotic cardiovascular disease in
the general population [11]. For example, levels of CRP,
E-selectin (which mediates leukocyte recruitment and
rolling in inflamed tissues), and adipose tissue cytokines
such as adiponectin and leptin are known to be altered
in patients with the metabolic syndrome [36]. Adipo-
nectin enhances insulin sensitivity, with favorable effects
on endothelial function, whereas leptin promotes ath-
erogenesis and is an independent risk factor for cardio-
vascular disease [40,41]. Leptin is produced primarily by
subcutaneous adipocytes, whereas adiponectin levels are
strongly correlated with visceral fat [40,41]. Childhood
ALL survivors treated with cranial radiotherapy have
been shown to have increased visceral fat versus
subcutaneous fat on computed tomography scans [42].
Other factors that may contribute to development
of cardiometabolic traits include sedentary lifestyle,
diet, and family history (both genetic and environmen-
tal influences) [43]. Studies of adult and pediatric
cancer survivors have found that survivors tend to be
less physically active compared with the general popu-
lation [44]. Dietary studies have generally reported low
adherence to recommended dietary guidelines in
childhood cancer survivors, suggesting another poten-
tial area for intervention [45]. Although the proportion
of survivors with a positive family history of cardiovas-
cular disease and/or diabetes was greater in HCT
survivors compared with non-HCT survivors, HCT
status remained a significant independent risk factor
in our multivariate analyses. Nevertheless, genetic
polymorphisms in selected pathways (eg, adiponectin
and leptin receptor genes) might be important in me-
diating the variation in risk in the general population
[46] as well as in cancer survivors [47].
In conclusion, we found that cardiometabolic
traits, including meeting metabolic syndrome criteria,
were more common in pediatric ALL survivors treated
with TBI-based HCT compared with those treated
with conventional chemotherapy. Manifestations ap-
peared at an early age and suggest that ALL survivors
treated with TBI or cranial radiotherapy should be
closely followed and screened for dyslipidemia and
diabetes, even if not overweight or obese by BMI stan-
dards. Alternative simple measures of central adipos-
ity, such as waist-to-hip ratio, may better identify
individuals at potentially greater risk. The important
role of central adiposity and inflammation in mediat-ing cardiometabolic complications is supported by
alterations in cytokine levels, corresponding to a proin-
flammatory state, including decreased adiponectin
levels, in HCT survivors.ACKNOWLEDGMENTS
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